Cargando…
P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430057/ http://dx.doi.org/10.1097/01.HS9.0000846716.90763.d0 |
| _version_ | 1784779641882411008 |
|---|---|
| author | Nakamura, R. Hendricks, R. Dokhaei, R. Susilo, M. Wilson, D. Trudel, S. Cohen, A. Harrison, S. J. Krishnan, A. Fonseca, R. Adamkewicz, J. I. Li, M. Wong, C. Cooper, J. Sumiyoshi, T. |
| author_facet | Nakamura, R. Hendricks, R. Dokhaei, R. Susilo, M. Wilson, D. Trudel, S. Cohen, A. Harrison, S. J. Krishnan, A. Fonseca, R. Adamkewicz, J. I. Li, M. Wong, C. Cooper, J. Sumiyoshi, T. |
| author_sort | Nakamura, R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430057 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94300572022-08-31 P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB Nakamura, R. Hendricks, R. Dokhaei, R. Susilo, M. Wilson, D. Trudel, S. Cohen, A. Harrison, S. J. Krishnan, A. Fonseca, R. Adamkewicz, J. I. Li, M. Wong, C. Cooper, J. Sumiyoshi, T. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430057/ http://dx.doi.org/10.1097/01.HS9.0000846716.90763.d0 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Nakamura, R. Hendricks, R. Dokhaei, R. Susilo, M. Wilson, D. Trudel, S. Cohen, A. Harrison, S. J. Krishnan, A. Fonseca, R. Adamkewicz, J. I. Li, M. Wong, C. Cooper, J. Sumiyoshi, T. P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB |
| title | P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB |
| title_full | P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB |
| title_fullStr | P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB |
| title_full_unstemmed | P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB |
| title_short | P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB |
| title_sort | p962: change in soluble bcma level may be a surrogate marker of early response to therapy in patients with relapsed/refractory multiple myeloma (rrmm): preliminary results from a phase i study of cevostamab |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430057/ http://dx.doi.org/10.1097/01.HS9.0000846716.90763.d0 |
| work_keys_str_mv | AT nakamurar p962changeinsolublebcmalevelmaybeasurrogatemarkerofearlyresponsetotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromaphaseistudyofcevostamab AT hendricksr p962changeinsolublebcmalevelmaybeasurrogatemarkerofearlyresponsetotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromaphaseistudyofcevostamab AT dokhaeir p962changeinsolublebcmalevelmaybeasurrogatemarkerofearlyresponsetotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromaphaseistudyofcevostamab AT susilom p962changeinsolublebcmalevelmaybeasurrogatemarkerofearlyresponsetotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromaphaseistudyofcevostamab AT wilsond p962changeinsolublebcmalevelmaybeasurrogatemarkerofearlyresponsetotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromaphaseistudyofcevostamab AT trudels p962changeinsolublebcmalevelmaybeasurrogatemarkerofearlyresponsetotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromaphaseistudyofcevostamab AT cohena p962changeinsolublebcmalevelmaybeasurrogatemarkerofearlyresponsetotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromaphaseistudyofcevostamab AT harrisonsj p962changeinsolublebcmalevelmaybeasurrogatemarkerofearlyresponsetotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromaphaseistudyofcevostamab AT krishnana p962changeinsolublebcmalevelmaybeasurrogatemarkerofearlyresponsetotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromaphaseistudyofcevostamab AT fonsecar p962changeinsolublebcmalevelmaybeasurrogatemarkerofearlyresponsetotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromaphaseistudyofcevostamab AT adamkewiczji p962changeinsolublebcmalevelmaybeasurrogatemarkerofearlyresponsetotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromaphaseistudyofcevostamab AT lim p962changeinsolublebcmalevelmaybeasurrogatemarkerofearlyresponsetotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromaphaseistudyofcevostamab AT wongc p962changeinsolublebcmalevelmaybeasurrogatemarkerofearlyresponsetotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromaphaseistudyofcevostamab AT cooperj p962changeinsolublebcmalevelmaybeasurrogatemarkerofearlyresponsetotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromaphaseistudyofcevostamab AT sumiyoshit p962changeinsolublebcmalevelmaybeasurrogatemarkerofearlyresponsetotherapyinpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromaphaseistudyofcevostamab |